19 March 2025 in NAR Molecular Medicine
Alternative splicing in genes associated with neuromuscular junction (NMJ) often compromises neuromuscular signal transmission and provokes pathological consequences. Muscle-specific receptor tyrosine kinase (MuSK) is an essential molecule in the NMJ. MUSK exon 10 encodes an important part of the frizzled-like cysteine-rich domain, which is necessary for Wnt-mediated acetylcholine receptors clustering at NMJ. MUSK exon 10 is alternatively spliced in humans but not in mice. We reported that humans acquired a unique exonic splicing silencer in exon 10 compared to mice, which promotes exon skipping coordinated by hnRNP C, YB-1, and hnRNP L. Here, we have dissected the underlying mechanisms of exon inclusion. We precisely characterized the exonic splicing enhancer (ESE) elements and determined the functional motifs. We demonstrated that SRSF6 and SRSF1 coordinately enhance exon inclusion through multiple functional motifs in the ESE. Remarkably, SRSF6 exerts a stronger effect than SRSF1, and SRSF6 alone can compensate the function of SRSF1. Interestingly, differentiated muscle reduces the expression of splicing suppressors, rather than enhancers, to generate a functional Wnt-sensitive MuSK isoform to promote neuromuscular signal transmission. Finally, we developed splice-switching antisense oligonucleotides, which could be used to selectively modulate the expression of MUSK isoforms toward a beneficial outcome for therapeutic intervention.
1 January 2020 in Proceedings for Annual Meeting of The Japanese Pharmacological Society
Introduction: We previously identified a novel magnetic organic compound, N,N'-bis(salicylidene)ethylenediamine iron [Fe(Salen)], as an anti-cancer agent with intrinsic magnetism. Fe(Salen) can generate heat, i.e. hyperthermia upon exposure to alternating magnetic field (AMF) like an induction cooker. The purpose of the study was to evaluate the antitumor effect of intra-arterial (i.a.) selective injection of Fe(Salen) by catheter with/without the AMF-induced hyperthermia or intra-venous (i.v.) injection. We also investigated the anticancer mechanism of Fe(Salen) and the therapeutic dose through toxicity study. Methods: Rabbit squamous cell carcinoma (VX2) cells were purchased from ATCC. Rabbit tumor model implanted with VX2 cells in the right femur was used. Western blotting, mitochondrial membrane potential and Immunocytochemistry for STAT3 subcellular distribution were performed. Results: Intra-arterial selective injection of Fe(Salen) by catheter showed the greater antitumor effect than that of i.v. injection. The combination of intra-arterial injection of Fe(Salen) and AMF exposure showed the greater effect than either Fe(Salen) or methotrexate (MTX) without AMF. Fe(Salen) showed antitumor effect via MEK/ERK/STAT3 signaling pathways. Conclusion: This is the first report that the effectiveness of Fe(Salen) was evaluated in the point of administration route. These results indicate the effective arterial injection of Fe(Salen) by catheter and the development of new strategy of simultaneous hyperthermia-chemotherapy.